|
|
|
|
|
 |
| Welcome
to Oncology Europe
23.11.2008 |
 |
This
website has been created to help inform and support physicians treating cancer
patients. It includes publications, conference reports, new data and concise
information
in the field of oncology.
|
|
What's new on Oncology Europe
|
|
|
|
Nov 14-15, 2008
ESH - EHA Tutorial on Haematological Malignancies
Dublin, Ireland
|
|
Read more... |
|
|
Site
of the
European Organisation
for Research and Treatment of Cancer
|
|
Read more...
|
|
  | Gastrointestinal Stromal Tumors (GIST)
24.11.2008
GIST are very rare tumors with a very poor prognosis. For a long time the only therapeutic option was surgery – if the tumor was detected at an operable stage, that is.
Read more...
 |
| Cetuximab for Head and Neck Cancer
21.11.2008
Survival for head and neck cancer patients with locally recurrent or metastatic disease is 6 to 9 months with currently available treatments. These poor outcomes have prompted investigations of novel therapies, including epidermal growth factor receptor (EGFR) inhibitors.
Read more...
|
| All the news on melanoma, breast and ovarian cancer
20.11.2008
Every two years in the autumn season, oncologists from all corners of the earth gather for the Congress of the European Society of Medical Oncology, Europe’s largest oncological association. The relevance of this congress is also evident in the fact that here even US-American study groups present new, as yet unpublished study results on a regular basis at this meeting.
Read more...
|
| What are the indications for growth factors?
19.11.2008
Growth factors such as granulocyte-colony stimulating factor (G-CSF) have made it possible to treat febrile neutropenia under cytostatic chemotherapy, in some cases even preventing it. The indications are outlined by guidelines of the EORTC, the ASCO and the NCCN, which to a large extent all correspond with each other; they are summarized in a practical algorithm for decision making in clinical practice. Jatros Hämatologie & Onkologie talked to Prof. DDr. Christoph Zielinski about these recommendations – and the advantages of guidelines in general.
Read more...
|
| Bevacizumab in Advanced Colorectal Cancer: A Challenge to the Current Paradigm
18.11.2008
To the Editor: The articles by Cassidy et al and Saltz et al describing the results of the NO16966 trial adressed critical issues in the management of advanced colorectal cancer (CRC), the former showing that capecitabine may be substituted for infusional fluorouracil in a first-line oxaliplatin-based regimen – a much less cumbersome therapeutic option for the patients –, and the second article reporting on the results of bevacizumab compared with placebo among patients receiving oxaliplatin-based chemotherapy, conducting a pooled analysis of capecitabine and oxaliplatin and oxaliplatin, fluorouracil, and leucovorin with or without bevacizumab. However, even though the primary end point of improved progression-free survival (PFS) met statistical significance (hazard ratio, 0,83; 97,5% CI, 0,72 to
0,95; P = 0,0023), the absolute improvement in median PFS of 1,4 months is not clinically meaningful. Furthermore, NO16966 did not show any improvement in response rate or overall survival.
Read more...
|
| Insights from a Negative Result
17.11.2008
The integration of taxanes into adjuvant chemotherapy regimens has incrementally improved the outcomes of patients with early-stage breast cancer (J Clin Oncol 2008; 26:44). Recently, researchers have focused on identifying the optimal taxane, schedule, and patient population to derive the greatest benefit from this approach (JW Oncol Hematol Nov 2007, p. 85, and N Engl J Med 2007; 357:1496).
Read more...
|
|
Next >
Service-Center: Power Point Presentations >
onco-europe-portal: New Stuff >
Oncological-Societies Europe >
All articles > 
Archive > |
|
|
|
|
|
|
|